Mycenax Biotech Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Public

  • Employees
  • 378

Employees

  • Stock Symbol
  • 4726

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.68
  • (As of Friday Closing)

Mycenax Biotech General Information

Description

Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards. The company's main operating region is located in Taiwan.

Contact Information

Website
mycenax.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 7F, No 66, Shengyi 2nd Road
  • Hsinchu County
  • Zhubei
  • Taiwan
+886 03
Primary Industry
Other Pharmaceuticals and Biotechnology
Stock Exchange
ROCO
Vertical(s)
Corporate Office
  • 7F, No 66, Shengyi 2nd Road
  • Hsinchu County
  • Zhubei
  • Taiwan
+886 03

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mycenax Biotech Stock Performance

As of 13-Nov-2026, Mycenax Biotech’s stock price is $0.68. Its current market cap is $141M with 207M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.68 $0.68 $0.60 - $1.17 $141M 207M 129K -$0.06

Mycenax Biotech Financials Summary

As of 30-Jun-2026, Mycenax Biotech has a trailing 12-month revenue of $26.3M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 196,456 238,299 288,939 236,995
Revenue 26,264 23,729 21,312 20,952
EBITDA (1,499) (4,463) (4,518) (11,545)
Net Income (12,294) (14,381) (14,556) (21,923)
Total Assets 102,810 104,281 102,432 122,702
Total Debt 35,248 34,275 26,864 23,636
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Mycenax Biotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Mycenax Biotech‘s full profile, request access.

Request a free trial

Mycenax Biotech Patents

Mycenax Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2020088346-A1 Aqueous pharmaceutical formulations Inactive 31-Oct-2018
US-20010026932-A1 Agonist anti-cd40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells; may be useful as antitumor agents Active 01-Feb-2000
US-7172759-B2 Agonist anti-cd40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells; may be useful as antitumor agents Inactive 01-Feb-2000
US-20070098720-A1 Bind to cell surface receptor, induce intracellular signal transduction, leading to activation of antigen presenting cells (apc) expressing cd40; cytotoxic effects, useful as antitumor agents Active 01-Feb-2000
US-7547438-B2 Bind to cell surface receptor, induce intracellular signal transduction, leading to activation of antigen presenting cells (apc) expressing cd40; cytotoxic effects, useful as antitumor agents Inactive 01-Feb-2000 A61K39/39541
To view Mycenax Biotech’s complete patent history, request access »

Mycenax Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mycenax Biotech Investments (1)

Mycenax Biotech’s most recent deal was a Joint Venture with Alfenax Biologics. The deal was made on 01-Dec-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Alfenax Biologics 01-Dec-2025 Joint Venture Drug Discovery
To view Mycenax Biotech’s complete investments history, request access »

Mycenax Biotech ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Mycenax Biotech’s complete esg history, request access »

Mycenax Biotech FAQs

  • When was Mycenax Biotech founded?

    Mycenax Biotech was founded in 2001.

  • Where is Mycenax Biotech headquartered?

    Mycenax Biotech is headquartered in Zhubei, Taiwan.

  • What is the size of Mycenax Biotech?

    Mycenax Biotech has 378 total employees.

  • What industry is Mycenax Biotech in?

    Mycenax Biotech’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Mycenax Biotech a private or public company?

    Mycenax Biotech is a Public company.

  • What is Mycenax Biotech’s stock symbol?

    The ticker symbol for Mycenax Biotech is 4726.

  • What is the current stock price of Mycenax Biotech?

    As of 13-Nov-2026 the stock price of Mycenax Biotech is $0.68.

  • What is the current market cap of Mycenax Biotech?

    The current market capitalization of Mycenax Biotech is $141M.

  • What is Mycenax Biotech’s current revenue?

    The trailing twelve month revenue for Mycenax Biotech is $26.3M.

  • What is Mycenax Biotech’s annual earnings per share (EPS)?

    Mycenax Biotech’s EPS for 12 months was -$0.06.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process